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ABSTRACT Extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) is a life-
threatening pathogen that causes serious global problems. Here, we investigated
two novel P. aeruginosa bacteriophages (phages), B-R656 and B-R1836, in vitro, in
silico, and in vivo to evaluate the potential of phage therapy to control XDR-PA clini-
cal strains. B-R656 and B-R1836 belong to the Siphoviridae family and exhibited
broad host ranges which could lyse 18 (64%) and 14 (50%) of the 28 XDR-PA strains.
In addition, the two phages showed strong bacteriolytic activity against XDR-PA host
strains from pneumonia patients. The whole genomes of B-R656 and B-R1836
have linear double-stranded DNA of 60,919 and 37,714 bp, respectively. The com-
plete sequence of B-R656 had very low similarity to the previously discovered P.
aeruginosa phages in GenBank, but phage B-R1836 exhibited 98% and 91% nucleo-
tide similarity to Pseudomonas phages YMC12/01/R24 and PA1/KOR/2010, respec-
tively. In the two in vivo infection models, treatment with B-R656 and B-R1836
enhanced the survival of Galleria mellonella larvae (50% and 60%, respectively) at
72 h postinfection and pneumonia-model mice (66% and 83%, respectively) at 12
days postinfection compared with untreated controls. Treatment with B-R656 or
B-R1836 also signiﬁcantly decreased the bacterial load in the lungs of the mouse
pneumonia model (6 log10 CFU and 4 log10 CFU, respectively) on day 5.
IMPORTANCE In this study, two novel P. aeruginosa phages, B-R656 and B-R1836,
were evaluated in vitro, in silico, and in vivo for therapeutic efﬁcacy and safety as an
alternative antibacterial agent to control XDR-PA strains collected from pneumonia
patients. Both phages exhibited potent bacteriolytic activity and greatly improved
survival in G. mellonella larva infection and a mouse acute pneumonia model. Based
on these results, we strongly predict that these two new phages could be used as
fast-acting and safe alternative biological weapons against XDR-PA infections.
KEYWORDS Galleria mellonella infection, Pseudomonas aeruginosa, Siphoviridae,
bacteriophage, bioﬁlm, mouse acute pneumonia, phage therapy
The increase in multidrug-resistant (MDR) pathogens, in particular the ESKAPE(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens, is a major
public health concern around the globe (1). Pseudomonas aeruginosa is an opportu-
nistic pathogen that has emerged as a major threat, causing a variety of acute
infections in the hospital environment (2). This bacterium is associated with ventilator-
associated pneumonia, burn wound infections, osteochondritis, and urinary tract in-
fections. In particular, extensively drug-resistant P. aeruginosa (XDR-PA) causes chronic
lung infections in immunocompromised patients with cystic ﬁbrosis (CF), and has
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contributed to high morbidity and mortality in these patients (3, 4). XDR was deﬁned
as nonsusceptibility to at least one agent in all but two or fewer antimicrobial
categories (i.e., strains remain susceptible to only one or two categories) (5).
These organisms are notoriously difﬁcult to treat and have led to treatment failures
because of their intrinsic (e.g., efﬂux pumps, -lactamases, and carbapenemases) and
acquired (e.g., horizontal transfer and mutational resistance) resistance mechanisms to
a wide variety of antibiotics (6, 7). Therefore, novel therapeutic approaches for treating
multidrug-resistant pathogen infections, including P. aeruginosa, are urgently needed.
With the rapid emergence of antibiotic-resistant strains of pathogenic bacteria world-
wide, the use of bacteriophages (phages), which are viruses that infect bacteria, has
been renewed as an alternative therapeutic option.
The application of phages as therapeutic agents to control pathogens is not a new
concept. Since the discovery of phages by Frederick Twort in 1915 and Félix d’Herelle
in 1917, phage therapy was actively performed in the former Soviet Union and in
Eastern Europe for decades, and it is still used today as a promising alternative to treat
several infections, especially in Georgia (8–10). Phages have several advantages over
conventional antibiotics, such as their easy isolation, cost-effectiveness, and absolute
host speciﬁcity, as well as the fact that they are obligate bacterial viruses that self-
multiply, do not damage the normal microbiota, and have no known adverse side
effects (11–14).
Various animal studies have been conducted to evaluate the safety and efﬁcacy of
phage therapy for serious clinical pathogens, including Acinetobacter baumannii (15),
Pseudomonas aeruginosa (16, 17), Staphylococcus aureus (18), Enterococcus faecium (19),
Escherichia coli (20), and Klebsiella pneumoniae (21). In 2006, phage cocktails targeting
Listeria monocytogenes were ﬁrst approved by the U.S. Food and Drug Administration
as antibacterial food additives to be used on ready-to-eat meat and poultry products
(22). Recently, the Phagoburn project (http://www.phagoburn.eu/) of clinical trials
conducted by various European countries and pharmaceutical companies aimed to
develop phage cocktails to treat infectious diseases caused by E. coli and P. aeruginosa
in burn patients. The evolution of phage-resistant bacteria is one of the major hurdles
associated with phage therapies (23). Accordingly, therapeutic use of phage cocktails
has been recently proposed to solve the limitation in phage host ranges and reduce the
development of phage-resistant mutants (23). However, isolation and identiﬁcation of
novel, well-characterized single phages with a broader antibacterial spectrum and
strong lytic activity are vitally important for generation of phage cocktails (24).
In recent studies, the therapeutic potential of P. aeruginosa phages against
multidrug-resistant P. aeruginosa was investigated in applications using phages in
either single or cocktail treatments (14, 25, 26), synergy of phage therapy with antibi-
otics (27), and disruption of pseudomonal bioﬁlms by phages in both in vitro and in vivo
models (28). Especially, in previous studies for human trials of P. aeruginosa phages as
therapeutic agents, Wright et al. applied phage therapy to treat P. aeruginosa-
associated chronic otitis (29) and Chan et al. reported therapeutic application of phage
on an aortic Dacron graft with chronic infection caused by P. aeruginosa (30).
To date, the complete genomes of approximately 76 Siphoviridae phages infecting
P. aeruginosa are available in the National Center for Biotechnology Information
database (https://www.ncbi.nlm.nih.gov/genome/; 1 October 2018). Several studies
concerning the therapeutic potential of phages against P. aeruginosa have been
reported, including some studies using phage therapy for pulmonary infections caused
by multidrug-resistant (MDR) P. aeruginosa in animal models (26, 31, 32). However,
there have been few studies on the activity of P. aeruginosa phages on XDR-PA isolates
from patients with pneumonia. In this work, we isolated and characterized two novel
P. aeruginosa phages, B-R656 and B-R1836, and evaluated their therapeutic potential
to control XDR-PA in patients with pneumonia using Galleria mellonella infection and a
mouse acute pneumonia model.
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RESULTS
In vitro characterization of the two phages. The morphological characteristics
determined using TEM indicated that the two P. aeruginosa phages B-R656 and
B-R1836, isolated from hospital sewage, belong to the Siphoviridae family, and both
phages had an icosahedral head approximately 62 nm in diameter and a tail approx-
imately 195 nm in length (n 10) (Fig. 1). The host spectra of phages B-R656 and
B-R1836 were determined using spot testing and efﬁciency of plating (EOP) assays,
and the phages formed clear or turbid plaques of 2 to 3 mm against 18 (64%) and 14
(50%) of the 28 XDR-PA clinical strains tested, respectively (see Table S1 in the
supplemental material). Nineteen of 28 XDR-PA clinical isolates formed plaques when
exposed to B-R656 and B-R1836. The in vitro sensitivities of phages were not equal
in 16 of 28 strains. Nine out of 28 strains were insensitive to both phages. Phages
B-R656 and B-R1836 had adsorption rates of 99% within 5 min and 10 min,
respectively (Fig. 2A) and a burst size of 253 and 499 PFU per infected cell, and both
phages had a latent period of 30 min (Fig. 2B).
In cell lysis and stability analyses, phages B-R656 (Fig. 2C) and B-R1836 (Fig. 2D)
inhibited bacterial growth at all MOIs at 6 h, except for B-R1836 at an MOI of 0.1. In
particular, both phages exhibited strong lysis activity at an MOI of 10 (OD600 0.16 and
OD600  0.18, respectively, at 6 h). The phages maintained a high stability of 99% at
4°C for 1 h and exhibited stabilities of 34% and 64%, respectively, at 50°C for 1 h (Fig.
S2). In the pH stability tests, the phages had stabilities of 53% and 84%, respectively, on
day 30 at pH 7. Moreover, phage B-R1836 retained a notable stability of 52% at pH 4
and 75% at pH 10 on day 30, but phage B-R656 showed relatively low stabilities of
33% at pH 4 and 12% at pH 10 on that day (Fig. S3).
In bioﬁlm-disruption ability, B-R656 (Fig. S4A and B) and B-R1836 (Fig. S4C and D)
also signiﬁcantly reduced the host bacterial bioﬁlms from 0.98 to 0.10 and from 1.21 to
0.26 at OD590 (****, P  0.0001).
In silico analysis of the two phages. The whole genomes of phages B-R656 and
B-R1836 were sequenced using a 454 GS Junior sequencer. The organization of the
genomes is represented in Fig. 3A and B in a circular form using DNAPlotter, and their
putative open reading frames (ORFs) are listed in Tables S2 and S3. The complete
genome of each phage has a linear double-stranded DNA, with B-R656 having 60,919
bp (31,270 read lengths and 238-fold coverage) and a GC content of 58.7% and
B-R1836 having 37,714 bp (2,498 read lengths and 267-fold coverage) and a GC
content of 64.25%. Bioinformatics analysis of both phage genomes identiﬁed 113 and
59 putative ORFs, respectively, and only 9 ORFs exhibited homology with genes of
other phages with annotated functions in GenBank. The annotated ORFs of both
phages contain morphogenesis genes (phage B-R656: orf 45, orf 63, orf 64, and orf 76;
B-R1836: orf 23, orf 30, orf 31, orf 32, orf 40, orf 46, and orf 49), phage DNA replication
FIG 1 Morphological images of B-R656 (A) and B-R1836 (B) acquired using transmission electron
microscopy. Bar  100 nm.
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and metabolism genes (phage B-R656: orf 17, orf 18, orf 23, and orf 80; B-R1836: orf
12 and orf 13), and lysis genes (phage B-R656: orf 40). Also, phage B-R656 had one
predicted tRNA (tRNA-Gly), while phage B-R1836 had no identiﬁed tRNAs. The com-
plete genomes of phages B-R656 and B-R1836 were compared to other P. aerugi-
nosa phage genomes using BLASTN from the National Center for Biotechnology
Information (NCBI). The complete sequence of phage B-R656 had 16% sequence
similarity (BLAST E value cutoff of 0.1) with those of P. aeruginosa phage phi1 (GenBank
accession number KT887557.1) and phage D3 (GenBank accession number AF165214.2)
but was not signiﬁcantly similar to that of other previously reported P. aeruginosa
phages (Fig. 3C). The genome sequence of phage B-R1836 had 98% and 91%
nucleotide similarity (BLAST E value cutoff of 0.1) to P. aeruginosa phages YMC12/01/
R24 (GenBank accession number MH643778.1) and PA1/KOR/2010 (GenBank accession
number HM624080.1), respectively (Fig. 3D). Although most of the phage ORFs were
putative genes, genes related to toxin and lysogeny-related genes in the two phage
genomes were not detected by the NCBI database.
In vivo efﬁcacy of the two phages in Galleria mellonella model. Galleria mello-
nella larvae were used as a surrogate animal infection model to evaluate the in vivo
FIG 2 In vitro characterization of B-R656 and B-R1836. (A and B) Adsorption rates (A) and one-step growth curves (B) of B-R656 () and
B-R1836 (). (C and D) Kinetics of cell lysis by B-R656 (C) and B-R1836 (D) in XDR P. aeruginosa strains YMC11/02/R656 and YMC11/11/R1836,
respectively. The host bacteria were infected with B-R656 or B-R1836 at MOIs of 0.1, 1, and 10. The data represent the mean  standard
deviation from triplicate experiments.
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therapeutic efﬁcacy of two P. aeruginosa phages, B-R656 and B-R1836, against
XDR-PA clinical strains. As shown in Fig. 4A and B, the G. mellonella larvae infected with
strains YMC11/02/R656 (1 105 CFU/ml) and YMC11/11/R1836 (1 105 CFU/ml)
showed 100% mortality at 24 h, and treatment with phages B-R656 (Fig. 4A) and
FIG 3 Genome organization of B-R656 (A) and B-R1836 (B) and genome comparisons of B-R656 (C) and B-R1836 (D) with their closest related
bacteriophages. Circular maps (A and B) prepared using DNAPlotter. The outer ring shows the ORFs of the phages and their transcription direction. The inner
rings indicate the GC content (black) and GC skew (, green; , purple). The genome alignments (C and D) of the bacteriophages were prepared using Easyﬁg
software, version 2.1.
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B-R1836 (Fig. 4B) (1 107 PFU/ml, MOI  100, 1 h postinfection) resulted in statisti-
cally signiﬁcantly improvement of the survival rate to 50% (**, P 0.0022) and 60% (***,
P  0.0003), respectively, at 72 h against each host XDR-PA strain. The survival rates of
the phage-treated groups at an MOI of 10 were 10% and 27%, respectively, at 72 h but
FIG 4 In vivo efﬁcacy of B-R656 and B-R1836 against XDR P. aeruginosa YMC11/02/R656 and YMC11/11/R1836 strains
in a Galleria mellonella infection model. Survival curves of G. mellonella larvae treated with B-R656 (A and C) or
B-R1836 (B and D) at an MOI of 100 (1 107 PFU/ml), 10 (1 106 PFU/ml), or 1 (1 105 PFU/ml) 1 h postinfection
(1 105 CFU/ml). G. mellonella larvae were monitored at 12-h intervals for 48 or 72 h. The percentage of G. mellonella
survival was determined using the log rank (Mantel Cox) test (**, P  0.0022; ***, P  0.0003). The data represent the
mean  standard deviations (error bars) from three independent experiments with 10 animals per treatment.
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showed no signiﬁcant differences from the bacterium-infected groups, and the phage-
treated groups at an MOI of 1 at 1 h postinfection showed 100% mortality at 36 h.
Treatment with phages B-R656 (Fig. 4C) and B-R1836 (Fig. 4D) at an MOI of 100
against each other’s host P. aeruginosa strain showed survival rates of only 10% and
30%, respectively, at 24 h. The larvae injected with buffer (PBS  SM) or phage only
(1 107 PFU) showed no mortality up to 72 h.
The histology of larval tissues was determined by staining at 72 h of in vivo efﬁcacy
assays and was analyzed to determine the therapeutic effects of phages B-R656 (Fig.
S5A) and B-R1836 (Fig. S5B). Infected larval tissues (1 105 CFU/ml) showed
melanized nodules in many areas, including the fat body well and the muscle layer, but
tissues of phage-treated larvae (MOI  100, 1 h postinfection) did not demonstrate
notable melanization or damage. The tissues of larvae injected with phage only
(1 107 PFU/ml) or buffer (PBS  SM) also showed no toxicity or damage (Fig. S5).
Therapeutic efﬁcacy of the two phages in a mouse model of acute pneumonia.
To evaluate the in vivo therapeutic potential and safety of the phages, we used a mouse
model of acute pneumonia caused by XDR-PA host strains. Phages B-R656 (Fig. 5A)
and B-R1836 (Fig. 5B) signiﬁcantly improved the survival rate of mice with acute
pneumonia. The phage-treated groups (MOI  10 at 4 h postinfection) showed high
survival rates of 66% and 83%, respectively, on day 12, but animals in the bacterium-
infected groups all died by day 3 postinfection. The groups injected with phage only
(1 107 PFU/ml) or buffer (PBS  SM) exhibited no mortality or loss of body weight
(Fig. S6).
Histological changes and cytokine levels. The histological changes and immune
responses due to phage therapy were assessed using H&E staining and cytokine (TNF-
and IL-6) analysis, respectively. The bacterium-infected group had more severe hem-
orrhaging in the alveolar space and alveolar wall thickening on days 1 and 5 than the
phage-treated groups. The phage-only-injected group showed histological changes on
days 1 and 5 similar to those of the buffer (PBS  SM)-injected group (Fig. 6).
FIG 5 Therapeutic efﬁcacy of B-R656 (A) and B-R1836 (B) in a mouse model of acute pneumonia
caused by XDR P. aeruginosa YMC11/02/R656 and YMC11/11/R1836 strains. Female C57BL/6 mice were
divided into the following six groups (n  6 per group): buffer-only inoculation (PBS  SM) group,
bacterium-only infection (1 108 CFU/ml) group, phage-only treatment (1 109 PFU/ml) group, and
phage treatment (MOI  10, 1, and 0.1) groups 4 h postinfection. The black arrow indicates a second
cyclophosphamide (CP) administration and the ﬁrst bacterial infection. Log rank (Mantel-Cox) test (****,
P  0.0001).
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The levels of TNF- and IL-6 in the lungs of bacterium-infected or phage-treated
mice were comparatively higher than in the buffer-injected group on day 1 (****, P 
0.0001; **, P 0.0024). However, these cytokine levels were signiﬁcantly reduced at day
5, and no signiﬁcant differences were detected among the experimental groups at that
time point (Fig. S7 and S8).
Bacterial counts in mouse lungs. To assess the in vivo bacteriolytic activities of the
two phages, the number of viable bacteria in the lungs of mice with acute pneumonia
was measured on days 1 and 5. As shown in Fig. 7, phages B-R656 and B-R1836
exhibited excellent elimination of the XDR P. aeruginosa host strains. The bacterial load
decreased by 2 log10 CFU (from 9.8 to 7.4 log10 CFU; ****, P  0.0001) after treatment
with phage B-R656 (Fig. 7A) and by 1 log10 CFU (from 7.7 to 6.4 log10 CFU; **, P 
0.0038) after treatment with phage B-R1836 (Fig. 7B) compared to the bacterium-
infected group on day 1. Additionally, the phages decreased the bacterial load by 6
log10 CFU (from 6.6 to 0.8 log10 CFU; ****, P  0.0001) and 4 log10 CFU (from 5.9 to
1.3 log10 CFU; ****, P  0.0001), respectively, on day 5. Moreover, complete bacterial
clearance was seen in some mice in the phage-treated group on day 5. No viable
bacteria were detected in the lungs of the buffer- and phage-only groups (data not
shown) on day 1 or 5.
FIG 6 Histological analysis of lung sections from mice treated with B-R656 (A) or B-R1836 (B). Mice were sacriﬁced on
either day 1 or 5. Lung sections were stained with hematoxylin and eosin and observed using an optical microscope at
a magniﬁcation of 10.
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DISCUSSION
XDR Pseudomonas aeruginosa is one of the most common Gram-negative patho-
gens causing nosocomial infections and is a major public health concern because it
possesses numerous resistance mechanisms, including beta-lactamases, carbapen-
emases, and efﬂux pumps (33, 34). As there is renewed interest in phages as therapeutic
tools, we isolated two novel P. aeruginosa phages speciﬁcally targeting XDR-PA clinical
isolates. The 28 XDR-PA strains used in this study were collected from various clinical
samples of patients with pneumonia and exhibited resistance to most antibiotics (see
Table S1 in the supplemental material). All of them were resistant to carbapenems, one
of the best choices for treatments of multidrug-resistant Gram-negative bacteria,
including imipenem (MIC, 16 g/ml) and meropenem (MIC, 16 g/ml) (Table S1).
These strains showed different PFGE patterns (Fig. S1).
FIG 7 Bacterial counts in lung sections on days 1 and 5 from mice treated with B-R656 (A) or B-R1836
(B). One-way ANOVA followed by Tukey’s multiple-comparison test was used to compare the bacterial
counts (****, P  0.0001; **, P  0.0038).
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We initially isolated eight P. aeruginosa phages from sewage water using XDR-PA as
the host bacteria. Morphology determined using TEM revealed that all phages were of
the Siphoviridae family within the Caudovirales order. Two of the 8 phages, B-R656 and
B-R1836, exhibited a wide host range and strong bacteriolytic activities against the P.
aeruginosa clinical strains and were examined in detail in vitro, in silico, and in vivo to
evaluate them as potential therapeutic phage agents.
In the in vitro experiments, B-R656 and B-R1836 exhibited a relatively broader
host spectrum than other phages targeting MDR P. aeruginosa strains (35–37), and
these phages showed signiﬁcant growth-inhibitory activity against host XDR-PA strains.
Host range is an important parameter for initial screening of new effective phages
against target bacteria, and this spectrum was conﬁrmed using both spot tests and EOP
assays (38, 39).
In previous studies, the results of EOP assays have not always correlated with those
of spot tests on collected pathogenic strains (38, 40). However, we found that the range
and ratios of EOP values of both phages were relatively similar to the results of the
plaque clarity values in the spot test against the P. aeruginosa strains used in the study
(Table S1). Therefore, we suggest that these two methods may be complementarily
applied to primary selection of new phages that possess broad and strong bacteriolytic
activity.
In the adsorption and one-step kinetics of both phages (B-R656 and B-R1836),
B-R1836 presented burst size that was approximately two times higher than that of
B-R1836 (Fig. 2B) while B-R1836 adsorbed to the host cell more slowly than B-R656
(Fig. 2A). Moreover, these two phages exhibited relatively higher burst size than other
P. aeruginosa phages JG024 (180 PFU per infected cell) (41) and C11 (11 PFU per
infected cell) (42). Therefore, B-R656 and B-R1836 showed better potential to be
used for the control of XDR-PA strains, as both of these phages could infect a large
number of host bacteria at the same time, and this could also reduce the potential for
the emergence of phage-resistant bacteria.
Among the physiological properties of phages, temperature and pH stability could
be considered important factors for the survival of phages during infectivity and
storage (43). Therefore, phages that have high stability at various temperatures and pH
values could be selected as some of the best candidates for application as sanitizers or
alternative therapeutic agents (44). In this study, B-R656 and B-R1836 showed higher
stability than other Pseudomonas phages (35, 36) at various temperatures (for 1 h) and
pH values (for 30 days) (Fig. S2 and S3). These data can be used for optimizing storage
and therapeutic application of phages under various physiological conditions.
Bioﬁlm formation by pathogens is a major problem, causing chronic infectious
diseases that are difﬁcult to treat in health care settings due to antibiotic resistance (45).
In particular, bioﬁlm-producing P. aeruginosa causes severe chronic lung infections in
immunocompromised individuals and patients with cystic ﬁbrosis (45, 46). Many
phages also possess antibioﬁlm activity, and several studies on Pseudomonas phages
that eradicate bacterial bioﬁlms have been reported (30, 47–49). Our phages, B-R656
and B-R1836, could also efﬁciently remove bioﬁlms of host XDR-PA strains (Fig. S4).
The bioﬁlm disruption ability of these phages could be used as a biocontrol agent, not
only to prevent bioﬁlm formation on medical devices in hospital environments but also
to control bioﬁlm-related infections.
The bioinformatics data of the two phage genomes revealed that phage B-R656
possesses a novel gene composition with 16% sequence similarity to other known P.
aeruginosa phages in the NCBI database (Fig. 3C). On the other hand, phage B-R1836
has 91% sequence similarity to the complete genomes of known phages (Fig. 3D).
However, the genomes of both phages include many unknown genes because func-
tional identiﬁcation of phage genes in the genome databases is inadequate. Neverthe-
less, some of the putative genes of these phages exhibited sequence relatedness and
similar genomic organization to the genomes of other known phages, indicating that
they evolved through horizontal exchange of genes with other phages (50, 51).
In vivo treatment with B-R656 and B-R1836 signiﬁcantly increased the survival
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rate in the G. mellonella larva infection (Fig. 4) and mouse pneumonia (Fig. 5) models
using XDR-PA clinical strains and reduced histologic damage to the bacterium-
challenged larval tissues (Fig. 6; also Fig. S5). Recent studies have demonstrated the
therapeutic efﬁcacy of phages against P. aeruginosa strains using G. mellonella larvae
(13, 52, 53). Especially, Beeton et al. (13) and Forti et al. (53) reported assessments of in
vivo phage therapy by phage cocktails. In the application of monophages, phage KT28
at an MOI of 100 also increased the survival of G. mellonella against both non-CF and
CF pseudomonas strains (52); however, the survival rates of phage KT28 were signiﬁ-
cantly lower than those of two phages in our study.
In our study, we found that B-R656 and B-R1836 were less effective against each
other’s strains than their original host strains (Fig. 4C and D). Moreover, this result was
notably similar to that of the clarity of host spectrum and EOP values of the two phages
against their host strains (Table S1). These data indicate that G. mellonella larvae can be
used as a surrogate model to initially screen effective phages before mouse experi-
ments. Furthermore, because the innate immune responses of G. mellonella to patho-
genic infections are very similar to those of mammals (54), G. mellonella larvae can be
used as a more simplistic and manageable system than vertebrate models to evaluate
infections with various pathogens (55).
To date, several studies on the therapeutic efﬁcacy of phages against P. aeruginosa
clinical strains using mouse lung infection models have been reported (26, 32, 53,
56–59). Our results also showed that treatment with the two novel phages signiﬁcantly
increased survival in the mouse acute pneumonia model (Fig. 5). In previous studies
using monophages, treatments with PAK-P3 (56) and PAK-P1 (32) led to higher survival
rates (MOI of 10 at 2 h postinfection) than our phages; however, it should be noted that
the mice were treated with phage (MOI of 10) at 4 h postinfection.
In the mouse acute pneumonia model, phages B-R656 and B-R1836 signiﬁcantly
reduced the bacterial loads of the host bacteria in the lungs (Fig. 7). Additionally, the
histologic features of each group accurately reﬂected the therapeutic effects of each
phage in terms of survival and bacterial clearance (Fig. 6). Moreover, there were no
adverse effects observed due to phage treatment in this study.
Conclusions. In the present study, two novel siphoviridal P. aeruginosa phages,
B-R656 and B-R1836, were investigated for their in vitro physiological characteristics,
in silico bioinformatic properties, and in vivo therapeutic effects against XDR-PA isolates
from pneumonia patients using two animal models. Overall, both phages showed
strong bacteriolytic activity and therapeutic efﬁcacy in vitro and in vivo against the
XDR-PA clinical strains, as well as pseudomonal bioﬁlm disruption. This work strongly
suggests that these two novel phages can be used for treating patients with pulmonary
infections caused by clinical P. aeruginosa strains. Furthermore, the physiological and
genetic studies of both phages provide insights to further the application of phages as
therapeutic alternatives for XDR-PA infections.
MATERIALS AND METHODS
Bacterial strains. The 28 XDR-PA strains were isolated from sputum, urine, and endotracheal aspirate
clinical samples from pneumonia patients at a university hospital in South Korea. The XDR clinical isolates
were identiﬁed using matrix-assisted laser desorption ionization–time of ﬂight mass spectrometry
(MALDI-TOF; Vitek MS system; bioMérieux, Marcy l’Etoile, France). Antimicrobial susceptibility testing of
the isolates was performed using the VitekN132 system (bioMérieux) and the Clinical and Laboratory
Standards Institute (CLSI) disk diffusion method (76). Pulsed-ﬁeld gel electrophoresis (PFGE) with the
CHEF-DR-II system (Bio-Rad Laboratories, Hercules, CA, USA) was used to determine the genomic DNA
clonality of the clinical isolates, and the PFGE patterns were analyzed using InfoQuest FP software
(version 4.50; Bio-Rad Laboratories, Inc.) (see Fig. S1 in the supplemental material). All collected XDR-PA
clinical strains were resistant to most antibiotics tested, including the carbapenems (imipenem and
meropenem). In particular, XDR-PA strains YMC11/02/R656 and YMC11/11/R1836, isolated from sputum
samples of patients with pneumonia, were used as the host strains to evaluate the in vitro and in vivo
therapeutic potential of phages B-R656 and B-R1836. The antimicrobial susceptibility proﬁles of all
XDR-PA strains used in this study are listed in Table S1.
Isolation and puriﬁcation of phage infecting XDR-PA strains. Phages capable of lysing XDR-PA
clinical strains were isolated from sewage water at a hospital in South Korea as described previously (60).
Brieﬂy, a suspension of host strains, P. aeruginosa YMC11/02/R656 and YMC11/11/R1836, in 4 ml of
Luria-Bertani broth (LB) medium (Difco, Detroit, MI, USA) adjusted to an OD600 of 0.5 was mixed with 1
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ml of sewage solution and incubated at 37°C for 12 h with shaking. The lysate was centrifuged at
12,000 g for 10 min at 4°C and ﬁltered using a 0.22-mmembrane (Millipore Corporation, Bedford, MA,
USA) to remove cell debris. Phage plaques were obtained using the double layer method (61). Puriﬁca-
tion of phages from single plaques was repeated at least three times using the process described above
until homogeneous plaques were obtained. To concentrate the puriﬁed phages, the phage solution was
treated with NaCl (ﬁnal concentration, 1 M; Merck) and polyethylene glycol 8000 (ﬁnal concentration,
10%; Sigma, St. Louis, MO, USA) and incubated at 4°C for 12 h. The concentrated phages were collected
through ultracentrifugation at 12,000 g for 1 h at 4°C and resuspended in 1 ml of sterilized sodium
chloride-magnesium sulfate (SM) buffer (100 mM NaCl, 8 mM MgSO4, 2% gelatin, 50 mM Tris-HCl, pH 7.5).
The phage stocks were titrated through plaque assays using the double layer method (61). The
concentrated phage stocks in SM buffer were stored at 4°C and used for in vitro and in vivo experiments.
Among the eight XDR-PA-lysing phages (B-P54, B-R24, B-R656, B-R960, B-R1561, B-R1836,
B-R2928, and B-R3040) which were isolated in this study, two phages (B-R656 and B-R1836) were
selected and further evaluated for their in vitro and in vivo therapeutic effects, as they exhibited wider
host range and stronger bacteriolytic activity.
Transmission electron microscopy. The morphology of the puriﬁed phage particles was analyzed
using transmission electron microscopy (TEM) as described previously (60). Brieﬂy, concentrated phage
solution was mounted on 300-mesh copper grids, stained with uranyl acetate, and analyzed using TEM
(JEOL JEM-1011; Tokyo, Japan) at 80 kV.
Adsorption and one-step growth kinetic analyses of phages. The adsorption rate and one-step
growth kinetic analyses of B-R656 and B-R1836 were performed as previously described, with some
modiﬁcations (62). Brieﬂy, for the adsorption rate test, host bacterial suspension (105 CFU/ml) was mixed
with phage solution at an MOI of 0.001 and incubated at 37°C. Samples of the mixture (100 l) were
taken at 1, 2, 3, 4, 5, and 10 min and centrifuged immediately (12,000 g, 10 min). The titer of
unadsorbed phages of supernatants was determined using the double-layer agar plate method (61). For
one-step growth kinetics, host bacterial cells were cultured in 5 ml LB medium (105 CFU/ml) and added
to phage solutions at an MOI of 0.001. After incubation for 5 min, supernatant including free phages was
removed by centrifugation (12,000 g, 10 min), and pellet was resuspended in 5 ml fresh LB medium.
Subsequently, culture samples (100 l) were collected at 5-min intervals for 100 min. Phage titration of
samples was immediately examined using the double-layer agar plate method (61).
Host range of phages. To determine the host range of isolated phages (P. aeruginosa phages
B-R656 and B-R1836) against the XDR-PA clinical isolates, the spot test was used as described
previously with some modiﬁcations (62). Brieﬂy, aliquots of 5 l phage solution (a ﬁnal titer of 1 105
PFU/ml) were serially diluted with SM buffer and spotted on lawns of various XDR-PA strains growing on
Luria-Bertani (LB) agar plates, which were then incubated at 37°C for 12 h. The plaques were classiﬁed
into one of three categories according to degree of clarity: clear (), turbid (), and no plaque (). The
efﬁciency of plating (EOP) for each phage on XDR-PA strains was determined using the double-layer agar
plate method and was calculated as the ratio of PFU of test strain (remaining 26 XDR-PA strains) to PFU
of host strain (YMC11/02/R656 and YMC11/11/R1836) (63).
Host cell lysis and stability of phages. Lysis assays using P. aeruginosa phages B-R656 and
B-R1836 were performed as described previously (60). Brieﬂy, the cultured host bacteria (OD600  0.2)
in fresh LB medium were mixed with the phage in SM buffer at a multiplicity of infection (MOI) of 0.1,
1, or 10. The bacterial turbidity was measured at 1-h intervals for 6 h using spectrophotometry at 600 nm.
The thermal and pH stabilities of the phages were determined as described previously (60), and phage
titers were determined using the double-layer agar method. The thermal stability of phages was
measured after incubation at 4°C, 40°C, 50°C, 60°C, or 70°C for 1 h, and pH stability was measured after
1, 2, 3, 4, or 5 days and 1 month at pH 4, 5, 6, 7, 8, 9, and 10 at 4°C. Data are presented as percentage
of surviving phages, and tests were performed in triplicate.
Bioﬁlm formation and crystal violet assay. Assays for bioﬁlm formation and activity of phages
against bioﬁlms were performed as previously described, with modiﬁcations (64). For bioﬁlm formation
of host XDR-PA strains, 200 l of YMC11/02/R656 or YMC11/11/R1836 bacterial suspension was diluted
to an OD600 of 0.2 in LB broth, dispensed into each well of a sterile 96-well ﬂat-bottomed polystyrene
plate (Corning, New York, USA), and cultured for 48 h at 37°C. Negative-control wells were ﬁlled with LB
broth only. Plates were sealed to avoid water loss by evaporation, and medium was renewed every 12 h.
After incubation for 48 h, plates were gently washed three times with PBS to remove cell debris, and
200 l of LB broth, either alone or containing phage at 1 107 PFU/ml, was applied to each well and
incubated at 37°C for 12 h. Supernatant was then removed, and each well was gently washed three times
with PBS and air dried for 1 h. Plates were stained with 200 l of 0.1% crystal violet solution (Merck) in
PBS for 10 min, washed with PBS, and air dried for 1 h. Crystal violet dye was then eluted with 125 l of
30% (vol/vol) glacial acetic acid for 10 min. The absorbance of each well was measured at 590 nm using
UV spectrophotometry, and each experiment was repeated three times.
Phage whole-genome sequencing and bioinformatics analysis. The phage DNA was extracted
and puriﬁed according to the standard phenol-chloroform extraction protocol as described previously
(65). Whole-genome sequencing was conducted at ChunLab, Inc. (Seoul, South Korea), using a 454 GS
Junior genome analyzer (Roche Life Sciences, Branford, CT, USA), and de novo assembly was carried out
using Roche gsAssembler (version 2.6; Roche) and CLC Genomics Workbench (version 4.8; CLC bio,
Aarhus, Denmark). Open reading frames (ORFs) were predicted using the NCBI ORF ﬁnder (66) and
GenMark.hmm software (67). The putative functions of the predicted ORFs were identiﬁed using BLASTP
(E values of0.1) (68) and PSI-BLAST (E value of0.005) (http://www.ebi.ac.uk/Tools/sss/fasta/) from the
NCBI database (https://www.ncbi.nlm.nih.gov/). Genomic organizations and comparisons of phages were
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generated using DNAPlotter (69) and Easyﬁg software (version 2.1) (70), respectively. The tRNA genes
were predicted using the tRNAscan-SE program (71).
Phage therapy assay in a G. mellonella infection model. To evaluate the therapeutic efﬁcacy of
B-R656 and B-R1836 against XDR-PA strains, a Galleria mellonella larva infection was used as described
previously, with some modiﬁcations (72). G. mellonella larvae weighing 200 to 250 mg were selected
randomly and swabbed with 70% ethanol. They were fasted in a 90-mm petri dish in darkness at 37°C
for 24 h prior to the test. The larvae were divided into the following 6 groups of 10 larvae each: (i) control,
PBS (phosphate-buffered saline; Invitrogen) SM; (ii) bacterial infection, 1 105 CFU/ml; (iii) phage-only,
1 1010 PFU/ml; (iv), phage treatment at an MOI of 100, 1 107 PFU/ml; (v) phage treatment at an MOI
of 10, 1 106 PFU/ml; and (vi) phage treatment at an MOI of 1, 1 105 PFU/ml. A bacterial amount of
5 l (5 102 CFU) was injected into the last right-side proleg of the larvae using a 10-l Hamilton syringe
(701RN; Hamilton Bonaduz AG, Bonaduz, Switzerland), and the phages at 5 l (5 104 PFU) were
injected into the last left-side proleg at 1 h postinfection. The larvae were then incubated in the dark at
37°C in 90-mm plastic petri dishes. To compare the therapeutic efﬁcacies between B-R656 and
B-R1836, larvae injected with host bacteria at the same concentration were treated with different
phages, and the survival of the larvae was determined every 8 h for 72 h. The larvae were considered
dead when there was no movement in response to touch. All experiments were repeated three times.
Histological analysis of larvae was performed as previously described, with modiﬁcations (73). Brieﬂy,
G. mellonella larvae at 72 h were ﬁxed in 10% formalin for 5 days and embedded in parafﬁn. Tissues were
stained with hematoxylin and eosin (H&E), and morphological features of tissues were observed using an
optical microscope.
Phage therapy assay in a mouse acute pneumonia model. The efﬁcacy of phage therapy in a
mouse acute pneumonia model caused by XDR-PA clinical strains was determined as previously
described (74). Brieﬂy, C57BL/6 mice (female, aged 7 to 8 weeks) were randomly divided into the
following six groups (n  5 per group): buffer-only inoculation (PBS  SM) group, bacterium-only
infection (1 108 CFU/ml) group, phage-only treatment (1 109 PFU/ml) group, and phage treatment
(1 109 to 1 107 PFU/ml for MOIs of 10, 1, and 0.1). All mice were intraperitoneally injected with
cyclophosphamide (200 mg/kg of body weight; Sigma-Aldrich) at 48-h intervals before infection (75).
Mice were intranasally treated with 30 l of phage (MOI  10, 1 and 0.1) or SM buffer at 4 h after either
administration of 30 l of bacteria (1 108 CFU/ml) or PBS via the same route. All mice were anesthe-
tized via intraperitoneal injection of Zoletil-Rompun before each intranasal procedure. The mortality and
body weights of the mice were recorded for 12 days.
For bacterial counts in the lung, histology, and cytokine analyses, non-cyclophosphamide-treated
mice were randomly divided into the following four groups (n  10 per group): buffer-only inoculation
(PBS  SM) group, bacterium-only infection (1 108 CFU/ml) group, phage-only treatment (1 109
PFU/ml) group, and phage treatment (1 109 PFU/ml for MOI  10). None of the groups was injected
with cyclophosphamide, and their body weights were measured for 12 days. After bacterial infection or
phage treatment, ﬁve mice from each group were sacriﬁced on day 1 and the remaining ﬁve on day 5.
To determine the number of viable bacteria in the lungs, homogenates of the collected lungs were
serially diluted in PBS and plated on LB agar plates containing ampicillin (50 g/ml). Lung histology
assays were performed as previously described with modiﬁcations (56). Brieﬂy, the right lung tissues were
ﬁxed in 10% formalin for 48 h and embedded in parafﬁn. The 3-m-thick tissue sections were stained
with H&E and analyzed using an optical microscope. To evaluate immunogenicity against the bacteria
and phages, the levels of tumor necrosis factor alpha (TNF-) and interleukin 6 (IL-6) in the lung lysates
were quantiﬁed with the commercial DuoSet kit (R&D Systems).
Ethics statement. All animal experiments followed the regulations of the Institutional Animal Care
and Use Committee of Yonsei University College of Medicine, Seoul, South Korea (IACUC approval no.
2014-0031-2).
Statistical analysis. Statistical analyses were performed with GraphPad Prism software (version 6;
San Diego, CA, USA). The log rank (Mantel-Cox) test was used for survival curves. One-way ANOVA
followed by Tukey’s test was used to compare bacterial counts and cytokine levels. Differences in bioﬁlms
were analyzed using the two-tailed t test, and P values of 0.05 were considered signiﬁcant.
Accession number(s). The complete genomes of B-R656 and B-R1836 were deposited into the
GenBank database under accession numbers KT968831.1 and KT968832.1, respectively.
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